Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and ¹⁸F-FDG-PET/CT

Figure 3

Measurement of the glucose metabolism. Quantitative analysis demonstrates decreasing tumor-to-muscle ratio of ¹⁸F-FDG during treatment with carboplatin and sunitinib, respectively. In sunitinib-treated tumors, differences to the controls were significant and highly significant at therapy days 4 and 9 ( and , respectively) (b), whereas in carboplatin-treated tumors, the tumor-to-muscle ratio of ¹⁸F-FDG uptake was significantly lower than in the control tumors at day 9 after therapy start (a). (c) Linear regression analysis showing a significant decrease in the tumor-to-muscle ratio of ¹⁸F-FDG during carboplatin treatment (R² = 0.46, slope: −0.08, ). (d) A significant decrease in the tumor-to-muscle ratio of ¹⁸F-FDG is observed during sunitinib treatment in the linear regression analysis (R² = 0.57, slope: −0.10, ). (e) Representative ¹⁸F-FDG-PET-CT images (transverse plane) showing high ¹⁸F-FDG uptake in the tumor of an untreated control mouse and a decrease in the uptake in carboplatin and sunitinib-treated tumors over time.

(a)

(b)

(c)

(d)

(e)